Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.67 |
| ▸ | PRKCG | P05129 | 1/20 | 0.67 |
| ▸ | PRKCB | P05771 | 1/20 | 0.67 |
| ▸ | IL1R1 | P14778 | 1/20 | 0.67 |
| ▸ | PRKCA | P17252 | 1/20 | 0.67 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.67 |
| ▸ | PRKCH | P24723 | 1/20 | 0.67 |
| ▸ | PRKCI | P41743 | 1/20 | 0.67 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.67 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.67 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.67 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.67 |
| ▸ | SHMT1 | P34896 | 6/20 | 0.53 |
| ▸ | SHMT2 | P34897 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30635009 | 0.83 | NPSR1 (0.63) | NPSR1PRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL2548186 | 0.83 | NPSR1 (0.63) | NPSR1PRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL22637490 | 0.82 | PRKD3 (0.62) | NPSR1PRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL30775593 | 0.82 | PRKD3 (0.62) | NPSR1PRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL2552765 | 0.81 | GAA (0.74) | NPSR1TLR7GAARAB9ANPC1 | |
| SCHEMBL2555429 | 0.80 | TLR7 (0.70) | NPSR1TLR7GAARAB9ANPC1 | |
| SCHEMBL2550683 | 0.78 | TLR7 (0.64) | NPSR1TLR7GAARAB9ANPC1 | |
| SCHEMBL20241724 | 0.77 | MAPT (0.63) | NPSR1PRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL31703937 | 0.76 | TLR7 (0.58) | NPSR1PRKD3PRKCGPRKCBIL1R1 | |
| SCHEMBL31610110 | 0.75 | PRKD3 (0.57) | NPSR1PRKD3PRKCGPRKCBIL1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200125564-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2020-04-23 | — | — | US | disclosed |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2020-01-28 | — | — | US | disclosed |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-09-04 | — | — | US | disclosed |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2018-07-12 | — | — | US | disclosed |
| US-9926325-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-03-27 | — | — | US | disclosed |
| EP-3176171-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2552920-B1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20150315199-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2015-11-05 | — | — | US | disclosed |
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8871761-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | EUROSCREEN S.A. (BE) | 2014-10-28 | — | — | US | disclosed |
| EP-2552920-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | Euroscreen S.A. (BE) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023530-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
| WO-2011121137-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | EUROSCREEN S.A. (BE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | NPSR1 29/4885PRKD3 179/4885PRKCG 578/4885 |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | NPSR1 28/4885PRKD3 155/4885PRKCG 646/4885 |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | NPSR1 29/4885PRKD3 179/4885PRKCG 578/4885 |
| US-20150315199-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | NPSR1 29/4885PRKD3 179/4885PRKCG 578/4885 |
| US-20130023530-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | NPSR1 29/4885PRKD3 179/4885PRKCG 578/4885 |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | NPSR1 28/4885PRKD3 155/4885PRKCG 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.